- Teva plans to cut roughly 80 positions at its Runcorn plant in the U.K., although 20 new specialist positions would be added under the plan, according to the Liverpool Echo.
- The overall goal is to increase the use of technology and automated processes, which requires workers with specialized expertise.
- The Runcorn site produces sterile products used in treatment of respiratory diseases as well as some of Teva's multiple sclerosis drugs.
The planned cuts at the Runcorn plant is part of a larger strategic reorganization announced last year by CFO Eyal Desheh. Desheh said Teva would be closing about three dozen factories over the next five years, according to FiercePharma Manufacturing. The Israeli-American company wants to cut $2 billion in expenses.
With Teva's acquisition of the generics Actavis unit from Allergan for $40.5 billion in July, the company may move forward with further shake-ups as it integrates.
Teva acquired the Runcorn site in 2006.